These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. FK 506 in the treatment of steroid- and OKT3-resistant rejection in renal transplant recipients: reduced dosage and anti-infective prophylaxis. Kliem V; Eberhard OK; Oldhafer K; Schlitt HJ; Behrend M; Schaumann D; Pichlmayr R; Koch KM; Brunkhorst R Transplant Proc; 1996 Dec; 28(6):3166-8. PubMed ID: 8962227 [No Abstract] [Full Text] [Related]
49. A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants. Flechner SM; Goldfarb DA; Fairchild R; Modlin CS; Fisher R; Mastroianni B; Boparai N; O'Malley KJ; Cook DJ; Novick AC Transplantation; 2000 Jun; 69(11):2374-81. PubMed ID: 10868643 [TBL] [Abstract][Full Text] [Related]
50. A single center experience with mycophenolate mofetil in the prevention of renal allograft rejection. Behrend M; Lück R; Köthe P; Pichlmayr R Transplant Proc; 1996 Dec; 28(6):3110-1. PubMed ID: 8962205 [No Abstract] [Full Text] [Related]
51. A prospective randomized trial of OKT3 vs ATGAM induction therapy in pancreas transplant recipients. Stratta RJ; Taylor RJ; Weide LG; Sindhi R; Sudan D; Castaldo P; Cushing KA; Frisbie K; Radio SJ Transplant Proc; 1996 Apr; 28(2):917-8. PubMed ID: 8623461 [No Abstract] [Full Text] [Related]
52. Simulect, calcineurin inhibitor, mycophenolate mofetil, and prednisone is more effective than OKT3, calcineurin inhibitor, hycophendate mofetil, and prednisone in African American kidney recipients in reducing acute rejections and prolonging graft survival. Kumar AM; Fa K; Vankawala R; Vora M; Kode RK; Pankewycz OG; Lattavi MR; Fyfe B; Damask AM; Ferry E; Stabler S; Tomeny MB; Phillips K; Lingaraju R; Kumar MS Transplant Proc; 2001; 33(7-8):3195-6. PubMed ID: 11750370 [No Abstract] [Full Text] [Related]
53. Cost-effectiveness of OKT3 induction therapy in cadaveric kidney transplantation. Alsina J; Bover J; Grinyó JM Am J Kidney Dis; 1996 Dec; 28(6):958. PubMed ID: 8957053 [No Abstract] [Full Text] [Related]
54. OKT3 salvage therapy in a quadruple immunosuppressive protocol in cadaveric renal transplantation. D'Alessandro AM; Pirsch JD; Stratta RJ; Sollinger HW; Kalayoglu M; Maki DG; Belzer FO Transplantation; 1989 Feb; 47(2):297-300. PubMed ID: 2493176 [TBL] [Abstract][Full Text] [Related]
55. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study. Grino JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Mestre M; Torras J; Alsina J Am J Kidney Dis; 1992 Dec; 20(6):603-10. PubMed ID: 1462990 [TBL] [Abstract][Full Text] [Related]
56. No long-term benefit of low-dose OKT3 induction therapy in non to moderately immunized renal allograft recipients. Bemelman FJ; Yong S; Parlevliet KJ; Surachno S; Schellekens PT; ten Berge RJ Transplant Proc; 2002 Dec; 34(8):3165-7. PubMed ID: 12493407 [No Abstract] [Full Text] [Related]
57. A prospective randomized study comparing poly-ATG to mono-OKT3 clonal antibodies for the first rejection therapy after kidney transplantation: long-term results. Baldi A; Malaise J; Mourad M; Squifflet JP Transplant Proc; 2000 Mar; 32(2):429-31. PubMed ID: 10715467 [No Abstract] [Full Text] [Related]
59. OKT3 prophylaxis in kidney transplant recipients: drug monitoring by flow cytometry. Cinti P; Cocciolo P; Evangelista B; Orlandini AM; Bruzzone P; Renna Molajoni E; Cortesini R Transplant Proc; 1996 Dec; 28(6):3214-6. PubMed ID: 8962245 [No Abstract] [Full Text] [Related]
60. Renal allograft function and results with cyclosporine immunosuppression in recipients of single kidneys from cadaveric donors aged 12 to 24 months. Banowsky LH; Wright FH; Kothmann R; Floyd M; Vick S Transplant Proc; 1996 Aug; 28(4):2121-4. PubMed ID: 8769175 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]